The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 12, 2016

Filed:

Oct. 08, 2014
Applicant:

Advinus Therapeutics Limited, Bangalore, IN;

Inventors:

Mahesh Thakkar, Pune, IN;

Summon Koul, Pune, IN;

Debnath Bhuniya, Pune, IN;

Kasim Mookhtiar, Pune, IN;

Santosh Kurhade, Pune, IN;

Yogesh Munot, Pune, IN;

Tanaji Mengawade, Pune, IN;

Bheemashankar A. Kulkarni, Pune, IN;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 403/04 (2006.01); C07D 413/14 (2006.01); C07D 519/00 (2006.01); C07D 403/14 (2006.01); A61K 45/06 (2006.01); A61K 31/519 (2006.01); A61K 31/5377 (2006.01); A61K 31/553 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01);
U.S. Cl.
CPC ...
C07D 519/00 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 31/553 (2013.01); A61K 45/06 (2013.01); C07D 403/14 (2013.01); C07D 413/14 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01);
Abstract

The present disclosure provides hetero-bicyclic compounds of formula (I), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, hydrates, N-oxides, co-crystals, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by Bruton's tyrosine kinase (Btk) activity, The disclosure also relates to the process of preparation of compounds of Formula (I). These compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of Bruton's tyrosine kinase (Btk), such as inflammatory and/or autoimmune disorder, cell proliferation, rheumatoid arthritis, psoriasis, psoriatic arthritis, transplant rejection, graft-versus-host disease, multiple sclerosis, inflammatory bowel disease, allergic diseases, asthma, type 1 diabetes, myasthenia gravis, hematopoetic disfunction, B-cell malignancies, systemic lupus, erythematosus or other disorders.


Find Patent Forward Citations

Loading…